Journal
LUPUS SCIENCE & MEDICINE
Volume 5, Issue 1, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/lupus-2017-000246
Keywords
-
Categories
Funding
- NIH [AR060861, AR057781, AR065964, AI071651]
- National Natural Science Fund of China [81072477]
- Mayo Clinic Foundation
- Lupus Research Alliance
- Colton Center for Autoimmunity
Ask authors/readers for more resources
Objective The type I interferon pathway is activated in many patients with systemic lupus erythematosus (SLE), and anti-double-stranded DNA (dsDNA) and anti-RNA binding protein autoantibodies are correlated with high interferon-alpha (IFN alpha) activity. We studied whether antiphospholipid (APL) antibodies, which should not stimulate Toll-like receptors, are also associated with high levels of IFN alpha activity. Methods Serum IFN alpha activity was measured in patients with SLE using the WISH cell bioassay. IgG APL, anti-RBP and anti-dsDNA antibodies were measured in the clinical laboratory, and standard clinical cut-offs were used to define the positive results. Results High IFN alpha activity was associated with anti-RBP and anti-dsDNA antibodies in all three ancestral backgrounds. Strikingly, African-American subjects with a positive APL antibody test had higher IFN alpha activity than those without IgG APL antibodies. This was not shared with other ancestral backgrounds. This finding was independent of other autoantibody profiles, and clinical features did not differ between IgG APL antibody positive versus negative African-American patients. Conclusion The difference in association between IFN alpha activity and IgG APL status between ancestral backgrounds supports differences in molecular pathogenesis. This may suggest B cell hyperactivity in the setting of type I IFN in African-Americans and could suggest ways to individualise therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available